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DOI 10.1016/j.ccr.2010.02.027SUMMARYIn a screen of drugs previously tested in humanswe identified itraconazole, a systemic antifungal, as a potent
antagonist of the Hedgehog (Hh) signaling pathway that acts by amechanismdistinct from its inhibitory effect
on fungal sterol biosynthesis. Systemically administered itraconazole, like other Hh pathway antagonists,
can suppress Hh pathway activity and the growth of medulloblastoma in a mouse allograft model and
does so at serum levels comparable to those in patients undergoing antifungal therapy. Mechanistically,
itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism
distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation
of SMO normally caused by Hh stimulation.INTRODUCTION
The Hh signaling pathway is critical for embryonic growth and
patterning in organisms ranging from insects to mammals (Varjo-
salo and Taipale, 2008). Hh signaling also functions postem-
bryonically in tissue homeostasis through effects on stem or
progenitor cells (Beachy et al., 2004). Inappropriate activity of
the Hh signaling pathway also has been linked to tumor types
that arise sporadically or in genetically predisposed individuals
(Varjosalo and Taipale, 2008; Yauch et al., 2008).Significance
The inappropriate activity of the Hh signaling pathway noted
small-molecule antagonists of Hh pathway signaling. Such
consuming. With the identification of itraconazole, a common
pathway in vitro and in vivo, it may be possible to avoid some
ment of Hh pathway antagonists. Supporting the rapid entry of
dent cancers, serum levels that inhibit growth of tumors in mic
388 Cancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc.Response to the Hh protein signal is governed by Patched
(PTCH), a 12-pass transmembrane protein that restrains the
activity of Smoothened (SMO), a member of the 7-transmem-
brane family of serpentine receptors (Figure 1A). Hh protein,
when present (Taipale and Beachy, 2001), binds PTCH and
blocks its inhibition of SMO, thus permitting accumulation of
SMO in the primary cilium (Corbit et al., 2005; Rohatgi et al.,
2007), and causing activation of the Gli family of transcription
factors. Pathway activation via SMO thus can occur either by
Hh protein stimulation or through loss of PTCH activity, asin a variety of tumor types has prompted efforts to develop
drug development efforts, however, are costly and time-
ly used systemic antifungal, as a potent inhibitor of the Hh
of the expense and delay associated with de novo develop-
itraconazole into clinical trials in the treatment of Hh-depen-
e are comparable to those reported in humans.
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predisposition syndrome, BCNS (basal cell nevus syndrome,
associated with heterozygous mutation of the human PTCH
gene).
Cyclopamine and other small molecules that antagonize Hh
pathway activity (Chen et al., 2002a; Chen et al., 2002b; Cooper
et al., 1998; Frank-Kamenetsky et al., 2002; Incardona et al.,
1998; Taipale et al., 2000) have been found to act predominantly,
although not exclusively, by binding the essential pathway
component SMO. These small molecules have been effective
in blocking Hh pathway-dependent growth of transformed cells,
both in vitro (Taipale et al., 2000) and in vivo (Berman et al., 2002;
Dierks et al., 2008; Romer et al., 2004; Yauch et al., 2008; Zhao
et al., 2009), thus stimulating major efforts to develop small-
molecule antagonists of the Hh pathway as cancer therapeutics.
However, drug development is time-consuming and costly
(DiMasi et al., 2003; Frank, 2003), and we sought to circumvent
this delay and expense by identifying Hh pathway antagonists
among drugs that have been tested for toxicity in humans
or even approved for human use by the US Food and Drug
Administration (FDA).
RESULTS AND DISCUSSION
We screened a library of 2400 FDA-approved or post-phase I
drugs (Chong et al., 2006a; Chong et al., 2006b) (now part of
the Johns Hopkins Clinical Compound Library) for activity in
inhibition of Hh signaling. This screen made use of a reporter
cell line, Shh-Light2 (Taipale et al., 2000) (see Experimental
Procedures), which contains a stably integrated Gli-luciferase
reporter that responds to stimulation by SHHN, the active form
of the Sonic hedgehog (SHH) signaling protein.
Although several dozen hits were identified from preliminary
screening, only a few were active in pathway inhibition at con-
centrations achieved in humans. Among these the microtubule
inhibitors, including vinca alkaloids and their derivatives, consis-
tently acted as Hh pathway antagonists (see Figure S1 available
online). Their cytotoxic nature, however, precludes an extended
and continuous course of treatment, as may be required
for therapy of cancers by antagonism of Hh pathway activity
(Berman et al., 2002; Romer et al., 2004; Yauch et al., 2008).
A more promising candidate, itraconazole, was identified as
a potent inhibitor of Hh pathway activity with an IC50 of approx-
imately 800 nM (Figure 1B). This antifungal is commonly used in
clinical practice as an orally delivered systemic treatment that
can be sustained for months (Stevens, 2001).
Itraconazole inhibits 14-a-lanosterol demethylase (14LDM), by
a mechanism in which the triazole group of itraconazole coordi-
nates the heme Fe2+ in the cytochrome P-450 active site of
14LDM (Georgopapadakou and Walsh, 1996). 14LDM is critical
for the biosynthesis of ergosterol in fungi and cholesterol in
mammals (Lepesheva and Waterman, 2007) (Figure 1C). Itraco-
nazole is significantly more potent in inhibiting the fungal enzyme
(Lamb et al., 1999; Trosken et al., 2006) but has been shown to
decrease human cholesterol levels at high doses (Schneider
et al., 2007).To test whether azole antifungals in general act to
inhibit Hh pathway activity, we examined five other imidazole
and triazole antifungal drugs. We found that itraconazole was
by far the most potent inhibitor of Hh pathway activity, with anIC50 more than 10-fold lower than that of ketoconazole, its near-
est rival (IC50z9 mM; see Figure 1D and Table S1). Hydroxy-itra-
conazole, the major metabolite of itraconazole in humans, is
equally potent in its antifungal activity (Harvey et al., 1980;
Hostetler et al., 1993), and also inhibited Hh pathway activity
(IC50z1.2 mM; see Figure 1E). Interestingly, fluconazole, an anti-
fungal with similar potency for 14LDM as itraconazole (Lamb
et al., 1999; Trosken et al., 2006), shows no detectable inhibition
of Hh pathway activity, even at a level 50-fold higher than the IC50
of itraconazole. We thus conclude that azole antifungal drugs as
a general class are not inhibitors of Hh pathway activity.
The inability of fluconazole to inhibit Hh pathway activity,
despite a similar potency for inhibition of 14LDM as itraconazole,
suggests that the effect of itraconazole is not due to an effect on
cellular cholesterol biosynthesis. Curiously, however, we noted
that increasing serum levels in our assays blocked pathway inhi-
bition by itraconazole (Figure 2A). This blocking effect was
absent in lipid-depleted serum (Figure 2B), suggesting that a
factor removed by lipid depletion of serum can interfere with or
reverse the action of itraconazole. A similar interfering effect of
serum but not lipid-depleted serum was noted with pathway
activation by the small-molecule agonist SAG (Chen et al.,
2002b) (Figures S2A and S2B).
To investigate this serum effect further, we directly tested the
effects of cholesterol and its biosynthetic precursors lathosterol
and desmosterol (see Figure 1C). In cultured cell signaling
assays, our laboratory has shown that statins can inhibit Hh
signal response, but only if transient cyclodextrin pretreatment
is first used to deplete cellular sterols (Cooper et al., 2003); itra-
conazole in contrast does not require cyclodextrin pretreatment
to inhibit the Hh pathway. Furthermore, although the addition of
cholesterol to cyclodextrin pretreated cultures in lipid-depleted
serum reversed the inhibitory effects of statins on Hh response
(Figure 2C) and cell proliferation (Figures S2C–S2E), the inhibi-
tory effect of itraconazole was not reversed by supplementation
of cultures with up to 25 mM lathosterol or desmosterol (Figures
2D and 2E) or 250 mM cholesterol as an ethanolic solution or
in water-soluble form (Figures S2F and S2G). These results
further reinforce the conclusion that itraconazole inhibition of
Hh response is not mediated through inhibitory effects on sterol
biosynthesis.
We next considered whether specific lipoprotein particles in
serum might account for the reversal of itraconazole action on
the Hh pathway, and found that low-density lipoprotein (LDL)
but not high-density lipoprotein or very low-density lipoprotein
particles dramatically interfered with itraconazole action on Hh
pathway activity (Figures 3A–3C). The megalin member of the
LDL receptor family (Fisher and Howie, 2006; Hussain et al.,
1999) has been shown to bind and endocytose SHH (McCarthy
et al., 2002), suggesting the possibility that LDL may interfere
with itraconazole by affecting reception of the Hh signal. This is
unlikely, however, because itraconazole acts below the level of
the Hh receptor PTCH (see below); LDL furthermore interferes
with itraconazole action even in cells lacking PTCH (Figure 3D).
We thus conclude that the interfering effect of serum is not due
to reversal of a sterol biosynthetic defect, nor through a LDL-
mediated effect on Hh reception, but more likely through
sequestration of itraconazole by LDL lipoprotein particles, which
have been shown to sequester and interfere with the actionCancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc. 389
Figure 1. Itraconazole Inhibits Hh Signaling
(A) A schematic view of the Hedgehog (Hh) signaling pathway. In the absence of Hh, Patched (PTCH) suppresses Smoothened (SMO) function. Hh, when present,
binds to and inhibits PTCH, permitting SMO accumulation in the primary cilium (not shown) and causing activation of the pathway via the Gli family of transcription
factors. Ptch and Gli1 are themselves transcriptional targets of the pathway. Oxysterols (dashed green bracket) act between PTCH and SMO, as pathway
activators, whereas statins (dashed red bracket) act downstream of PTCH and at or upstream of SMO, as pathway inhibitors. SAG and cyclopamine activate
and inhibit the pathway, respectively, by binding to the transmembrane domain of SMO. Activators and inhibitors of the pathway are labeled in green and
red, respectively.
(B) Hh signaling assays. Luciferase reporter activity under the control of an 8x-Gli binding site in the Shh-Light2 reporter cell line was measured upon stimulation
with SHHN-containing medium. Itraconazole blocked Hh pathway activity (IC50z800 nM).
(C) Schematic view of mammalian cholesterol biosynthesis from 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA). Statins inhibit HMG-CoA reductase
whereas azole antifungal drugs inhibit 14a-lanosterol demethylase (14LDM), as indicated. Lathosterol and desmosterol are cholesterol precursors downstream
of 14LDM.
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Figure 2. Inhibition of Hh Signaling by
Itraconazole Is Not Mediated by Effects on
Cholesterol Biosynthesis
(A) Increasing serum concentrations attenuated
the inhibitory activity of itraconazole but not
KAAD-cyclopamine.
(B) The attenuating effect of serum was abolished
by lipid depletion (LD).
(C) Shh-Light2 cells were pretreated with
methyl-b-cyclodextrin (MbCD) 8 mM in DMEM
for 45 min to remove sterols from the cell surface
(Cooper et al., 2003). Lovastatin, an HMG-CoA
reductase inhibitor, inhibited Hh pathway activity
induced by SHHN. Cholesterol, in ethanol
solution, reversed the pathway inhibition due to
lovastatin.
(D and E) Lathosterol, desmosterol, and choles-
terol failed to rescue Hh pathway inhibition by
itraconazole under low (D) or lipid-depleted (E)
serum conditions.
All signaling assays were performed with Shh-
Light2 cells and data are mean of triplicates ± SD.
See also Figure S2.
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(Remsen and Shireman, 1981; Shu and Nichols, 1979) and
p-dimethylaminoazobenzene (Chen et al., 1979).
We investigated the target of itraconazole action within the Hh
pathway by examining cells with the Ptch gene disrupted by in
frame fusion of lacZ (Goodrich et al., 1997; Taipale et al.,
2000). Loss of PTCH function in these cells causes constitutive
pathway activity and consequent expression of b-galactosidase
through activation of the Ptch promoter. Itraconazole treatment
of these cells inhibited b-galactosidase expression at levels
similar to those required for inhibition of pathway activity in
SHHN-stimulated Shh-Light2 cells (IC50 z900 nM; Figure 4A).
These results indicate that itraconazole acts independently of(D) Among the azole antifungals, itraconazole was the most potent inhibitor of Hh pathway activity.
(E) Hydroxy-itraconazole, the major metabolite of itraconazole in mammals, also inhibited the Hh pathway (IC
with Shh-Light2 cells in 0.5% serum media and data are shown as the mean of triplicates and standard dev
Cancer Cell 17, 388–3and downstream of PTCH. In contrast to
Ptch/ cells, the inhibitory action of itra-
conazole was bypassed by expression
of SmoA1 (Taipale et al., 2000; Xie et al.,
1998), a constitutively active oncogenic
variant of murine SMO (Figure 4B), sug-
gesting that itraconazole does not act
downstream of SMO. To define further
the target of itraconazole action, we
combined itraconazole treatment with
pathway activation by overexpression of
SMO or by treatment with the oxysterols
20(S)- and 22(S)-hydroxycholesterol
(Corcoran and Scott, 2006; Dwyer et al.,
2007). We found that itraconazole
blocked pathway activity produced by
SMO overexpression (Figure 4C). Itraco-
nazole also completely blocked oxysterol
action (IC50 z270 nM; Figure 4D), sug-
gesting that oxysterols act on a target distinct from and
upstream of the target of itraconazole.
The ability to suppress pathway activity from SMO overex-
pression but not from SMOA1 suggests that itraconazole may
act by binding to SMO as an inverse agonist (Bond et al.,
1995; Costa and Herz, 1989); binding to SMO also could account
for itraconazole effects in Ptch/ cells, or in cells treated with
oxysterols. Therefore, we also examined the effect of itracona-
zole treatment on localization of SMO, which has been shown
to accumulate in the primary cilium upon Hh stimulation (Corbit
et al., 2005; Rohatgi et al., 2007; Figure 4E). We found that
itraconazole treatment dramatically reduced Shh-induced
accumulation of SMO in the primary cilium (Figure 4E), similar50z1.2 mM). All signaling assays were performed
iation (± SD). See also Figure S1 and Table S1.
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Figure 3. Low-Density Lipoprotein Modu-
lates the Hh Pathway Inhibitory Effects of
Itraconazole
(A and B) High-density lipoprotein (HDL, A)
100 mg/ml and very low-density lipoprotein
(VLDL, B) 6.5 mg/ml cannot reverse Hh pathway
inhibition by itraconazole.
(C and D) Titration of low-density lipoprotein (LDL)
up to 120 mg/ml rescues either induced Hh
pathway activity by SHHN ligand in Shh-Light2
cells (C) or constitutively active pathway in
Ptch/ cells (Goodrich et al., 1997; Taipale
et al., 2000) (D) from the inhibitory effects of itraco-
nazole. All signaling assays were performed in lipid
depleted 10% calf serum media for Shh-Light2
cells (A–C) and 0.5% fetal bovine serum media
for Ptch/ cells.
Data represent mean of triplicates ± SD.
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to cyclopamine, which induced accumulation of SMO in the
primary cilium (Rohatgi et al., 2009; Wang et al., 2009). The ability
of itraconazole to suppress SHH-induced accumulation of SMO
in the primary cilium is consistent with direct action of itracona-
zole on SMO for pathway inactivation.
Like itraconazole, cyclopamine inhibits pathway activity in
Ptch/ cells (Taipale et al., 2000), in cells treated with oxysterols
(Dwyer et al., 2007), and in cells overexpressing SMO (Taipale
et al., 2000), but not in SMOA1-expressing cells (Taipale et al.,
2000). As proposed above for itraconazole, cyclopamine and
many other antagonists act by binding to SMO (Chen et al.,
2002a; Chen et al., 2002b; Frank-Kamenetsky et al., 2002). We
therefore tested itraconazole for SMO binding using BODIPY-cy-
clopamine, a fluorescent cyclopamine derivative, and a cell line
that expresses SMO upon induction by treatment with tetracycline
(Dwyer et al., 2007). We found that BODIPY-cyclopamine binding
to SMO was not affected significantly by itraconazole, even at
10 mM, a concentration 12.5-fold higher than its IC50 (Figure 5A).
This contrasts sharply with the potent cyclopamine derivative,
KAAD-cyclopamine (IC50 = 20 nM), which reduced bound BOD-
IPY-cyclopamine to near-background levels at 200 nM (Figure 5A).392 Cancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc.Although itraconazole fails to compete
with BODIPY-cyclopamine, it could nev-
ertheless bind SMO at a distinct site
from cyclopamine. If so, itraconazole
conceivably could bind simultaneously
with cyclopamine or with other small
molecule agonists and antagonists that
bind at the cyclopamine site. Itraconazole
thus may synergize with cyclopamine or
other SMO antagonists in pathway inhibi-
tion and it may act noncompetitively with
SMO agonists that bind at the cyclop-
amine site. Indeed, we found that the
IC50 of KAAD-cyclopamine decreased
from 20 nM to 2 nM with increasing doses
of itraconazole (Figure 5B and Table S2),
and that the IC50 of itraconazole de-
creases from 800 nM to 130 nM withincreasing doses of KAAD-cyclopamine (Figure 5C and Table
S3). In addition, the maximal degree of pathway activation by
SAG, whose SMO binding site overlaps that of cyclopamine,
was reduced by increasing concentrations of itraconazole
without altering the SAG EC50 (Figure 5D and Table S4), indi-
cating that itraconazole acts as a non-competitive inhibitor
(Taylor and Insel, 1990). Itraconazole, in summary, behaves
like an inverse agonist, suppresses the accumulation of SMO
in the primary cilium, mutually enhances the potency of pathway
inhibition in combination with cyclopamine, and acts as
a noncompetitive inhibitor of pathway activation by SAG. These
characteristics of itraconazole are consistent with the binding of
itraconazole to SMO at a distinct site from that of cyclopamine.
Given that we have not demonstrated direct binding of itracona-
zole to SMO, the possibility remains that itraconazole may exert
its inhibitory action on SMO through other indirect mechanisms.
Having characterized the Hh pathway inhibitory activity of itra-
conazole in vitro, we examined its effect in vivo by systemic
treatment of animals subcutaneously engrafted with a primary
medulloblastoma from a Ptch+/; p53/ mouse. Medulloblas-
tomas from these mice depend on constitutive Hh pathway
activity for their growth (Berman et al., 2002; Goodrich et al.,
Figure 4. Mapping of Itraconazole Action
within the Hh Pathway
(A) Itraconazole inhibited constitutive Hh pathway
activity in Ptch/ cells, measured as expression
of b-galactosidase activity from the Ptch-lacZ
locus (Goodrich et al., 1997; Taipale et al., 2000).
The levels of b-galactosidase activity from cells
treated with KAAD-cyclopamine at 40 and 200 nM
(2x and 10x IC50) are shown as purple and red
lines, respectively.
(B) Shh-Light SmoA1 cells, stably expressing a
constitutively active SMO mutant, were resistant
to Hh pathway inhibition by itraconazole. Cyclop-
amine and forskolin (orange and blue lines,
respectively) were used as negative and positive
controls for the inhibition of SMOA1.
(C) Itraconazole and KAAD-cyclopamine both in-
hibited constitutive Hh pathway activation induced
by transient overexpression of SMO in NIH 3T3
cells.
(D) Itraconazole inhibited Hh pathway activity
induced by the combined oxysterols, 20(S)- and
22(S)-hydroxycholesterol (5 mM each). All sig-
naling assays were performed with Shh-Light2
cells in 0.5% serum media and data are shown
as the mean of triplicates ± SD.
(E) Representative immunofluorescent images of
NIHT-3T3 cells. SMO accumulated in primary cilia
upon stimulation with SHHN (arrowheads). This
accumulation was blocked by treatment with itra-
conazole. Insets show enlarged views of primary
cilia in the dashed box, with SMO and acetylated
tubulin channels offset. Arrows show primary cilia
with no SMO accumulation. As seen in the histo-
gram, the accumulation of SMO in 90% of
primary cilia of cells stimulated with SHHN, is
reduced to 5% in the additional presence of
itraconazole. The number of primary cilia con-
taining SMO over the total number of primary cilia
are shown above each bar.
Data represent mean of ten fields ± SD. The scale
bar represents 5 mm.
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pathway antagonists (Berman et al., 2002; Romer et al., 2004).
Treatment with itraconazole indeed inhibited growth of these
subcutaneous allografts, with similar inhibition of tumor growth
noted for animals treated with itraconazole at 100 mg/kg twice
per day (b.i.d.) or 75 mg/kg b.i.d. (Figure 6A). Consistent with
the synergistic effect of itraconazole and cyclopamine in vitro,
combined treatment with itraconazole and cyclopamine pro-
duced an even greater inhibition of tumor growth. Mice bearing
control tumors were euthanized after 18 days as the tumors
exceeded the size limits set forth by our Institutional Animal
Care and Use Committee.
At the end of the experiment, 4 hr after the last dose, we
obtained serum and tumors from three mice in each treatment
group. Itraconazole concentrations were measured using a
bioassay method based on antifungal activity (Hostetler et al.,
1992; Rex et al., 1991) that does not distinguish betweenitraconazole and hydroxy-itraconazole (Hostetler et al., 1993).
Itraconazole concentrations reported here therefore represent
a combined measurement of itraconazole and hydroxy-itracona-
zole effects. Serum itraconazole concentrations were similar
between the 100 mg/kg and 75 mg/kg groups (Figure 6B). Itraco-
nazole levels achieved in tumors (Figure 6C) were similar to drug
levels in serum, indicating that itraconazole has good tumor
tissue penetration. The area-under-the curve (AUC) values for
serum concentrations of itraconazole reached during a 24 hr
pharmacokinetic study (Figure 6D) were also similar for
itraconazole given at 100 mg/kg and 75 mg/kg (220 mg $ hr/ml
and 238 mg $ hr/ml, respectively). These findings are consistent
with previously published pharmacokinetic results (Hostetler
et al., 1992).
We also tested the ability of itraconazole to inhibit pathway
activity in tumor tissue in a separate experiment that made
use of mice bearing secondary subcutaneous medulloblastomaCancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc. 393
Figure 5. Itraconazole Acts at a Site Distinct
from the Cyclopamine-Binding Site of SMO
(A) BODIPY-cyclopamine (B-C) bound to tetracy-
cline-induced SMO in 293S cells as monitored
by FACS. As negative controls, the gray tracing
shows fluorescence of cells not treated with B-C
and the blue tracing (blue arrow) shows uninduced
cells treated with B-C; the black tracing (black
arrow) represents maximal fluorescence of cells
induced for SMO expression and treated with
B-C. Itraconazole treatment (no arrows) at con-
centrations up to 12.53 IC50 (10 mM) did not effec-
tively compete for B-C binding, whereas KAAD-
cyclopamine at 23 IC50 and 103 IC50 (40 nM
and 200 nM; tan and red arrowheads, respectively)
caused significant decreases in fluorescence.
(B and C) Synergistic action of itraconazole
and KAAD-cyclopamine. In signaling assays per-
formed with Shh-Light2 cells, the presence of itra-
conazole caused a downward shift in the IC50 of
KAAD-cyclopamine (from 21 nM to 1.8 nM in the
presence of 900 nM itraconazole; [B] and Table
S2); KAAD-cyclopamine caused a downward shift
in the IC50 of itraconazole (from 805 to 135 nM in
the presence of 30 nM KAAD-cyclopamine; [C]
and Table S3).
(D) KAAD-cyclopamine is a competitive inhibitor of
SAG, a known Hh pathway agonist, as shown by
shifts of the SAG EC50 by 5 and 13 fold at 40 nM and 100 nM concentrations of KAAD-cyclopamine. In contrast, itraconazole did not alter the SAG EC50
but decreased the maximal activity of SAG, thus acting as a noncompetitive inhibitor (see Table S4).
All signaling assays were performed with Shh-Light2 cells in 0.5% serum media and data represent mean of triplicates ± SD. See also Tables S2, S3, and S4.
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of tumor growth (see above). These mice were treated either
with 100 mg/kg itraconazole b.i.d. or 37.5 mg/kg cyclopamine
b.i.d. The treated tumors showed decreased Gli1 mRNA levels,
indicative of reduced Hh pathway activity as compared with
cyclodextrin vehicle-treated controls (Figure 6E).
To further assess the activity of itraconazole on suppression of
Hh-dependent tumors, we used K14-CreER; Ptch+/; p53 fl/fl
mice to generate endogenous basal cell carcinomas (BCC) of
the skin (see Experimental Procedures). BCC tumors generated
from these mice have increased levels of Hh pathway activity
and their growth is suppressed by Hh pathway inhibitors (Xiao
et al., 2009). Itraconazole treatment suppressed the growth of
the endogenous BCC tumors when compared with the cyclo-
dextrin vehicle control (Figure 7A). When itraconazole was
stopped after 18 days of treatment (Figure 7A), the tumors began
to grow again at a rate similar to that of vehicle-treated control
tumors. At the end of the study, tumors from itraconazole-
treated mice appeared to have greater levels of necrosis as
compared with tumors from vehicle-treated mice, based on
destruction of basophilic tumor cell nests and the eosinophilic
stroma surrounding these nests (Figure 7B). Tabulation of
necrosis scores, with a higher score indicating worse necrosis,
confirmed that histologically assessed necrosis was greater for
itraconazole-treated BCC as compared with vehicle-treated
tumors (Figure 7C).
The serum concentrations of itraconazole associated with an
antitumor effect in our in vivo studies are higher than those
reached in humans at regular therapeutic doses (Barone et al.,
1993) (i.e., 400 mg/day orally for 15 days). Similar high serum
levels of itraconazole (Sanchez et al., 1995), however, have394 Cancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc.been reported in patients treated for severe fungal infections.
This high-dose itraconazole therapy has ranged from 600 to
900 mg/day (Sanchez et al., 1995; Sharkey et al., 1991; Takagi
et al., 2001) over treatment periods ranging from 3 to 16 months,
with occasional toxicities that were manageable (Sharkey et al.,
1991). It is of interest that ketoconazole, another azole antifungal,
has been used as second-line therapy for androgen-indepen-
dent metastatic prostate cancer (Scholz et al., 2005; Trump
et al., 1989) at doses 3- to 6-fold higher than its normal dose
and with toxicities greater than those for high-dose itraconazole
(Sugar et al., 1987). The use of ketoconazole in this context is
believed to act by inhibiting androgen production, but we cannot
rule out the possibility of an effect on Hh pathway activity.
Hh pathway activity has been characterized as contributing to
growth of many tumor types (Varjosalo and Taipale, 2008; Yauch
et al., 2008). Recent studies in the mouse have shown that
another cancer, chronic myelogenous leukemia (CML), is depen-
dent on Hh signaling. SMO activity is necessary for maintenance
of CML stem cells and mouse and human CML that becomes
resistant to tyrosine kinase inhibitor therapy remains sensitive
to manipulation of SMO activity (Dierks et al., 2008; Zhao et al.,
2009).
The importance of the Hh pathway in tumor growth has led
to an active interest in the development of small-molecule Hh
pathway antagonists (Tremblay et al., 2009). Most of these mole-
cules are either cyclopamine derivatives or they antagonize
pathway by binding SMO at the same site as cyclopamine.
Recent clinical tests of one of these cyclopamine mimics,
GDC-0449 (Rudin et al., 2009; Von Hoff et al., 2009), produced
promising results, suggesting that Hh pathway inhibition may
represent an effective approach to cancer therapy. Further
Figure 6. Itraconazole Inhibits the Growth
of Hh-Dependent Medulloblastoma In Vivo
(A) Itraconazole, either alone or in combination
with cyclopamine, suppressed the growth of allog-
rafted medulloblastomas from a Ptch+/p53/
mouse, as compared with vehicle-treated tumors.
Treatments were given twice per day by oral
gavage. The number of tumors used in this exper-
iment were: Cyclodextrin control n = 8, itracona-
zole 100 mg/kg n = 12, itraconazole 75 mg/kg
n = 10, cyclopamine 37.5 mg/kg n = 10, itracona-
zole/cyclopamine n = 10. Data are expressed as
mean percentage change in volume ± standard
error of the mean (SEM).
(B and C) Mean serum and tumor itraconazole
levels obtained at the end of the allograft study in
(A) are shown in panels (B) and (C), respectively.
The dashed lines represent the minimum detect-
able levels of the assay; vehicle controls were at
or below these levels.
(D) Pharmacokinetics of itraconazole levels in serum
ofathymicnude miceafter one oraldoseof itracona-
zole 100 mg/kg or 75 mg/kg. All itraconazole levels
were obtained using the bioassay method (Clemons
et al., 2002; Harvey et al., 1980; Hostetler et al.,
1992; Rex et al., 1991). Data for itraconazole levels
in (B)–(D) represent the mean of three samples ± SD.
(E) Hh pathway is decreased in allografted
medulloblastoma tumors when treated with either
itraconazole or cyclopamine as compared to
cyclodextrin control treatment. Hh pathway was
monitored by Gli1 mRNA levels. Gli1 mRNA levels
of drug treatments were normalized to the mean
of Gli1 mRNA levels of cyclodextrin control. Treat-
ments were given twice per day for 4 days by oral
gavage. **p = 0.0197; ***p = 0.0386.
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term safety of such agents (Dlugosz and Talpaz, 2009).
Itraconazole has been studied for nearly 25 years, and we
therefore have a good understanding of its safety and potential
side effects. Furthermore, itraconazole is already used in human
patients at doses that produce serum concentrations like those
found to be effective in our murine medulloblastoma and BCC
models. It is worth noting that itraconazole acts at a distinct
site from cyclopamine; itraconazole and related compounds
may therefore represent a helpful adjunct or alternative to the
cyclopamine mimics currently under widespread development.
For these reasons, particularly its well-known safety profile, it
should be possible to quickly evaluate itraconazole either alone
or in combination with other targeted therapies or cytotoxic
agents in patients with tumors of known Hedgehog pathway
dependence.Cancer Cell 17, 388–3EXPERIMENTAL PROCEDURES
Cell Culture Assays for Hh Pathway
Activation
Shh-Light2 cell line (Taipale et al., 2000) is a clonal
NIH 3T3 cell line stably transfected with 83-Gli1-
binding site dependent firefly luciferase and Renilla
luciferase reporters. SmoA1 Light cell line is a clonal
subline of Shh-Light cells stably transfected with
oncogenic SmoA1 (Taipale et al., 2000). Shh-Light2cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% (v/v) calf serum, penicillin, streptomycin, L-glutamine supplemented
with Geneticin (Invitrogen) 400 mg/ml, and Zeocin (Invitrogen) 100 mg/ml. SmoA1-
Light cells were maintained in DMEM containing 10%(v/v) calf serum, penicillin,
streptomycin, L-glutamine supplemented with Geneticin 400 mg/ml and
Hygromycin (CalBiochem) 100 mg/ml. Ptch/ MEF cell line (Taipale et al.,
2000) was maintained in DMEM containing 10% fetal bovine serum, penicillin,
streptomycin, L-glutamine supplemented with Geneticin 400 mg/ml.
SHHN conditioned medium (CM) was prepared as previously described
(Maity et al., 2005). HEK293 CM was used for control. HEK293 CM was
prepared in the same manner as SHHN CM. Stock SHHN CM and HEK293
CM (for control) were diluted 10-fold with the appropriate media for various
Hh pathway signaling assays.
For SMO overexpression assay in NIH 3T3 cells, Smo, GFP, Gli-dependent
firefly luciferase reporter, and TK-Renilla luciferase reporter vectors have been
described previously (Taipale et al., 2000). Fugene 6 (Roche Applied Science)
was used for transient transfection of the vectors at a ratio of 4 ml:1.5 mg
(Fugene6:DNA). Each well of a 24 well multiwell plate was transfected with99, April 13, 2010 ª2010 Elsevier Inc. 395
Figure 7. Itraconazole Inhibits the Growth
of Hh-Dependent Basal Cell Carcinoma
In Vivo
(A) Compared with cyclodextrin vehicle-treated
tumors, itraconazole suppressed the growth of
endogenous basal cell carcinomas from a
K-14CreER;Ptch+/;p53 fl/fl mouse. Treatments
weregiven twiceperdaybyoral gavage.Gray arrow
indicates the day that itraconazole treatment was
stopped. The number of tumors used in this exper-
iment were as follows: Cyclodextrin control, n = 10;
itraconazole 100 mg/kg n = 20 until day 19 when
itraconazole treatment was discontinued then
n = 6 after some mice were euthanized and tumors
dissected for further examination (see Experimental
Procedures). For statistical analysis, pairwise com-
parisons of treatment arms were made for corre-
sponding day of treatment with the exception of
cyclodextrin control day 17 being compared with
itraconazole day 18. Data are expressed as mean
percentage change in tumor length ± SEM.
(B) Cyclodextrin control treated tumors showed
nests of well-organized tumor cells (arrowhead),
whereas itraconazole-treated tumors showed
greater evidence of necrosis as seen by destruction
of organized nests of basophilic tumor cells and
pyknosis (arrow) and destruction of eosinophilic
stroma lining the BCC nests (black arrowhead).
Images are H&E sections. The scale bar represents
100 mm.
(C) From the tumor growth inhibition study, BCC
tumors from itraconazole-treated mice (including
those that had itraconazole discontinued) show
more evidenceof necrosis than cyclodextrin control
treated tumors as measured by necrosis score (see
Experimental Procedures) with higher numbers
indicating worsening necrosis.
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for Fugene:DNA ratioof 3ml:10mg with 250 ng totalDNA per well of a 24-well plate.
All assays for Hh pathway activation were performed in 24 well tissue culture
plates. Cells were grown in 10% (v/v) serum media until completely confluent.
Drugs, 293 CM, and SHHN CM were diluted in DMEM containing 0.5% (v/v)
serum unless otherwise noted in main text and figure legends. Cells were
incubated for 40-46 hr with drug treatments, except for the comparison of
various azole (30 hr) and SMOA1 (30 hr) to minimize toxicity from the high
concentrations of azole antifungals and forskolin, respectively. After internal
normalization of firefly luciferase with tk-Renilla luciferase for each well, rela-
tive luciferase units were obtained by normalization of Hh pathway stimulated
cells with unstimulated cells (all other conditions being equal) grown on a sepa-
rate plate in parallel. All luminescence assays were performed on a Fluostar
Optima (BMG Labtech). Luminescence assays were performed according
to manufacturer’s instructions using Dual Luciferase Assay Reporter System
(Promega). b-Galactosidase activity of Ptch/ cells were obtained with
Galacto-Light Plus Reporter System (Applied Biosystems) per manufacturer’s
instructions. Total protein was obtained using BCA Protein Assay kit (Thermo
Scientific) according to the manufacturer’s instructions.
Dose-response curves and IC50 values were determined by fitting the data
with four parameter logarithmic nonlinear regression analysis with GraphPad
Prism software.396 Cancer Cell 17, 388–399, April 13, 2010 ª2010 Elsevier Inc.Fluorescent BOPDIPY-Cyclopamine
Competition Assays
Maintenance and induction of SMO in the
HEK293S cell line stably expressing a tetracycline
inducible Smo gene has been described previ-ously (Dwyer et al., 2007). After 2 days of SMO induction, cells were incubated
with BODIPY-cyclopamine 10 nM ± inhibitors at 37C for 4-6 hr. Cells were
trypsinized, washed with phosphate-buffered saline (PBS) after centrifugation,
pelleted by centrifugation and resuspended in 0.5% calf serum/phenol
red-free DMEM. BODIPY fluorescence was measured on FACSAria (Becton
Dickinson). Fluorescence-activated cell sorting data were analyzed with
FlowJo software.
Immunofluorescence
NIH 3T3 cells were grown to confluence on tissue culture treated glass cover-
slips (Fisher) and treated with various conditions for 6 hr as described previ-
ously for Hh pathway signaling assays. At the end of the incubation period,
samples were fixed in methanol at 20C and subsequently stained with
appropriate antibodies. The antibodies used were as follows: rabbit polyclonal
anti-SMO 1:750 dilution, mouse monoclonal anti-acetylated tubulin 1:1000
dilution (Sigma), AlexaFluor 488 goat anti-rabbit 1:667 dilution (Invitrogen),
and AlexaFluor 594 goat anti-mouse 1:667 dilution (Invitrogen). Details of
anti-SMO antibody have been described elsewhere (Kim et al., 2009).
Microscopy
Images for ciliary accumulation of SMO were obtained on a Zeiss LSM 510
Meta Confocal microscope at the Stanford Institute for Neuro-Innovation &
Cancer Cell
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were obtained with Zeiss Zen software. Cilia from these images were quanti-
fied manually.
For presentation of images, representative 3003 300 pixel portions of each
metafile were cut and maximum intensity overlay images of Z-stack were
produced using Zeiss Zen software. The cut images were enlarged using
Adobe Photoshop software. For inset images, portions were cut and enlarged
using Adobe Photoshop. Subsequently, red and green channels were offset
using ImageJ software. All images were then recombined and brightened
equally using Adobe Photoshop.
In Vivo Drug Treatment Studies
All mouse studies were approved by and conformed to the policies and
regulations of the respective Institutional Animal Care and Use Committees
at Stanford University and the Children’s Hospital Oakland Research Institute.
Study of Medulloblastoma Tumor Growth Inhibition
Primary medulloblastoma from Ptch+/; p53/ mouse was dissected, minced
and triturated through a 20G needle under sterile conditions. Tumor was mixed
in a 1:1 solution of PBS:growth factor reduced Matrigel (BD Bioscience) and
equal volumes were allografted subcutaneously into right and left flanks of
6 to 7 wk old female outbred athymic nude mice (Charles River Laboratories,
Wilmington, MA). Tumors were established with an average tumor volume of
each arm 110 mm3 before treatment. Tumors were measured with vernier
calipers every 3-4 days and tumor volume (Berman et al., 2002) was calculated
as (width 3 length 3 ([0.5 3 (length + width)]). Drinking water was acidified.
Animals were treated twice per day, 10-14 hr apart by oral gavage with equal
volumes of 40% (w/v) 2-hydroxypropyl-b-cyclodextrin (HPCD) solution as
control and drugs. Oral itraconazole solution 10 mg/ml (Ortho-Biotec) was
used for itraconazole 100 mg/kg arm. Oral itraconazole solution contains
40% (w/v) HPCD to solubilize itraconazole (Martin, 1999). For the itraconazole
75 mg/kg arm, oral itraconazole solution was diluted to 7.5 mg/ml with sterile
water. Cyclopamine was dissolved in 10% (w/v) HPCD/0.1 M sodium citrate/
phosphate solution (pH 3) (Feldmann et al., 2007) at a concentration of
3.75 mg/ml. For itraconazole 100 mg/kg-cyclopamine 25 mg/kg, cyclopamine
powder was dissolved in oral itraconazole 10 mg/ml solution to a final concen-
tration of 2.5 mg/ml. A one-way analysis of variance was used for comparing all
treatment arms with GraphPad Prism software.
Study of Treatment for Hh Pathway Inhibition
An untreated primary medulloblastoma allograft from the tumor growth study
was minced, digested into a single cell suspension with collagenase IV
(Worthington Biochemical), and stored in liquid nitrogen. Medulloblastoma
cells were thawed and incubated overnight in defined serum-free media
(Kalani et al., 2008) containing B-27 supplement without vitamin A(Invitrogen),
mouse EGF 20 ng/ml (Peprotech), mouse bFGF 20 ng/ml (Invitrogen), minimal
nonessential amino acids (Invitrogen), N-acetyl cysteine 60 mg/ml, Glutamax
(Invitrogen) in Neurobasal A medium (Invitrogen). Cells were pelleted, washed
with PBS, and mixed in 1:1 solution of PBS:growth-factor-reduced Matrigel
as noted above. Approximately 1.2 million cells were injected into the flank
of nude mice as noted above. Tumors were established and mice were
treated twice per day by oral gavage for 4 days. Drugs were prepared as noted
above.
Generation of Endogenous Basal Cell Carcinoma
Different mice carrying the K14-Cre-ER transgene (Metzger et al., 2005), the
floxed p53 allele (Jonkers et al., 2001), and the Ptch1+/ (Goodrich et al.,
1997) alleles were bred together for generating Ptch1+/; K14-Cre-ER;
p53fl/flmice. We treated these mice at age 6 weeks with 100 mg/day tamoxifen
administered intraperitoneally for three consecutive days. At 8 weeks of age,
Ptch1+/ K14-Cre-ER p53fl/fl mice were exposed to 4 Gy of ionizing radiation
(IR). Mice develop visible BCC tumors at 6 months of age.
Study of BCC Tumor Growth Inhibition
Four mice with a total of 20 visible BCC tumors were gavaged twice daily
with oral itraconazole solution (Ortho-Biotec) 100 mg/kg, for 18 days. Itraco-
nazole was discontinued on day 19, two mice were euthanized on day 19
and the tumors dissected for further examination and BCC tumors of thetwo remaining were followed until 22 days. Two mice with 10 BCC tumors
were treated with 40% w/v HPCD (Sigma) for an average of 22 days at
which point the mice were euthanized because of their large tumor size
that exceeded our animal care guidelines. We measured the change in
the long axis of BCC tumor size with calipers every 3 days (So et al.,
2004). Pairwise comparisons between cyclodextrin control and itraconazole
treatment arms were done using a two-sided unpaired t test with GraphPad
Prism software.Necrosis Scoring of BCC Tumors
Hematoxylin and eosin stained (H&E) sections of paraffin-embedded BCC
tumors after the growth inhibition study were examined for necrosis. Necrosis
was scored as follows: 0 = no evidence of necrosis with large basaloid cells;
1 = mild necrosis with nuclear pyknosis; 2 = moderate necrosis with < 25%
necrosis; 3 = severe necrosis with > 25% necrosis. After tabulation of necrosis
scores, pairwise comparison between cyclodextrin control and itraconazole
treatment tumors were made using a two-sided unpaired t test with GraphPad
Prism software.Itraconazole Levels
For the itraconazole pharmacokinetic study, 7- to 8-week-old female outbred
athymic nude mice were given one dose of itraconazole 100 mg/kg or 75 mg/
kg or equivolume of 40% HPCD solution at time = 0 hr point. At each time point,
three mice from each treatment arm were anesthetized, exsanguinated, blood
collected, and euthanized. Blood was allowed to clot and the resultant serum
used for bioassays to measure itraconazole levels. Serum from untreated athy-
mic nude mice was used for obtaining the standard curve for the bioassays.
Area under the curve (AUC) from 0–24 hr were calculated with GraphPad Prism
software with the trapezoidal rule method.
For itraconazole concentrations from the medulloblastoma allograft study,
serum from three mice of each treatment and control arm were obtained at
the end of the study in a similar manner to the pharmacokinetic study.
For itraconazole concentrations of tumors from the medulloblastoma
allograft study, mice were exsanguinated under isoflurane anesthesia and
perfused with PBS via the left ventricle to remove any blood that might
confound tumor itraconazole levels. Tumors were excised and frozen on dry
ice, ground, and extracted with solvent for drug assay as previously described
(Clemons et al., 2002). Serum and tissue antifungal itraconazole concentra-
tions were determined by bioassay method, with itraconazole standards, as
described elsewhere (Clemons et al., 2002; Harvey et al., 1980; Hostetler
et al., 1992; Rex et al., 1991).SUPPLEMENTAL INFORMATION
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